Penile squamous cell carcinoma (SCC) is a rare and aggressive urological malignancy. Advanced penile SCC requires multimodal management, including surgery and systemic therapy. Given its rarity, there have been few substantial advances in our understanding of the molecular and genomic drivers of penile SCC, especially for patients with relapsed or advanced disease. In this review, we discuss the molecular and genomic landscape of penile SCC, clinical trials in progress and implications for novel therapeutic targets. Future work should focus on preclinical models to provide a platform for investigation and validation of new molecular pathways for testing of therapeutics.
Future oncology (London, England). 2020 Jul 26 [Epub ahead of print]
Jiasian Teh, Ellen O'Connor, Jonathon O'Brien, Wei Mou Lim, Michael Taylor, Alexander Heriot, Robert Ramsay, Nathan Lawrentschuk
Division of Cancer Surgery, Peter MacCallum Centre, Melbourne, Victoria 3000, Australia., Department of Surgery, University of Melbourne & Royal Melbourne Hospital, Department of Urology, Melbourne, Victoria 3000, Australia., Sir Peter MacCallum Dept. of Oncology, University of Melbourne, Melbourne, Victoria 3000, Australia.